"I understand the challenges facing Teva and I am confident that,
together with the management team, we can address these challenges and
deliver on our commitment to creating value for our shareholders by
expanding Teva's businesses and delivering long-term growth," Vigodman
said in a statement.
Vigodman will fill the roles left vacant in late October by his
predecessor Jeremy Levin's ouster. Levin was pushed out of the position
less than 18 months in over disagreements on the company's strategy.
The 54-year-old currently serves as CEO of Makhteshim Agan Industries
(MAI), the world’s leading generic agrochemical company, where he will
remain until February 6. Prior to that, he served as the Strauss Group's CEO.